en · de · es · fr · pt
nad-notes.peptides4088.com › Info › Background And Peptide Identity — Explained

Background And Peptide Identity — Explained

By Editorial Desk · published 2026-03-01 · last reviewed 2026-04-17 · Info

This is a working overview of lyophilized, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-04-17. Anything still debated is marked as such rather than presented as settled.

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Analytical Methods and Material Handling

Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideModeled on tuftsin
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSeven residues
Approximate molecular massAround 750 DaDepends on counter-ion and hydration
Common formsLyophilized powderAlso described as aqueous solution
Primary origin of researchRussian laboratoriesMid-1990s onward

Selank Background and Peptide Chemistry

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Related pages on this site

Analytical Methods and Handling

Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.

Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.

Peptide Identity and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Supporting material

In the diet, β-glucans are a source of soluble, fermentable fiber – also called prebiotic fiber – which provides a substrate for microbiota within the large intestine, increasing fecal bulk and producing short-chain fatty acids as byproducts with wide-ranging physiological activities. This fermentation impacts the expression of many genes within the large intestine, which further affects digestive function and cholesterol and glucose metabolism, as well as the immune system and other systemic functions.

== Current Research and Future Implications == Currently, studies and experiments are being done to test for dedifferentiation-like abilities in mammalian cells, with hopes that this information can provide more insight into possible regenerative abilities in mammals. Dedifferentiation could spark innovation in regenerative medicine because it suggests that one's own cells can change cell fates, which would remove immunological response risks from treatment with allogeneic cells, or cells that are not genetically matched with the patient. A concept that has been explored for mammals is that of inducible dedifferentiation, which would make cells that do not naturally dedifferentiate be able to revert to a pluripotent or progenitor-like state. This is achieved by expressing the appropriate transcription factors in the cell and suppressing others. More information about this as well as the possible risks can be found here [1] .

The Wound Man is a surgical diagram which first appeared in European medical manuscripts of the fourteenth and fifteenth centuries. The illustration acted as an annotated table of contents to guide the reader through various injuries and diseases whose related cures could be found on the text's nearby pages. The image first appeared in a printed book in 1491 when it was included in the Venetian Fasciculus medicinae, likely Europe's first printed medical miscellany. Thereafter it circulated widely in printed books until well into the seventeenth century. The Wound Man has since become a recognisable figure in popular culture.

Sources: en.wikipedia.org

Supporting material

222Rn, 3.82 days, alpha decaying to... 218Po, 3.10 minutes, alpha decaying to... 214Pb, 26.8 minutes, beta decaying to... 214Bi, 19.9 minutes, beta decaying to... 214Po, 0.1643 ms, alpha decaying to... 210Pb, which has a much longer half-life of 22.3 years, beta decaying to... 210Bi, 5.013 days, beta decaying to... 210Po, 138.376 days, alpha decaying to... 206Pb, stable The radon equilibrium factor is the ratio between the activity of all short-period radon progenies (which are responsible for most of radon's biological effects), and the activity that would be at equilibrium with the radon parent. If a closed volume is constantly supplied with radon, the concentration of short-lived isotopes will increase until an equilibrium is reached where the overall decay rate of the decay products equals that of the radon itself. The equilibrium factor is 1 when both activities are equal, meaning that the decay products have stayed close to the radon parent long enough for the equilibrium to be reached, within a couple of hours. Under these conditions, each additional pCi/L of radon will increase exposure by 0.01 working level (WL, a measure of radioactivity commonly used in mining). These conditions are not always met; in many homes, the equilibrium factor is typically 40%; that is, there will be 0.004 WL of daughters for each pCi/L of radon in the air.

=== Pharmacokinetics === A single 40-mg oral dose of relugolix has been found to result in peak levels of relugolix of 29 ng/mL (47 nmol/L) after 1.5 hours. Steady-state levels are reached within 7 days with 40 mg/day relugolix administration. There is an approximate 2-fold accumulation of relugolix by 2 weeks of continuous administration. Food diminishes the oral bioavailability of relugolix by about 50%. Relugolix is a substrate for P-glycoprotein, which may have a limiting effect on its absorption and distribution. The plasma protein binding of relugolix is approximately 68 to 71% over a concentration range of 0.05 to 5 μg/mL. Relugolix is not a substrate for CYP3A4. The elimination half-life of relugolix is 36 to 65 hours across a dosage range of 20 to 180 mg/day. There is moderate to high interindividual variability in systemic exposure to relugolix. Relugolix is excreted mainly in feces (83%) and to a small degree in urine (4%). Only about 6% of a dose of relugolix is excreted unchanged.

=== Leadership under Brian L. Halla === National Semiconductor announced the appointment of Brian L. Halla as its chairman, president and CEO on May 3, 1996. Halla was then the head of LSI logic products division. Prior to LSI, he had been with Intel for 14 years. Halla reinforced Amelio's emphasis on the expertise of National Semiconductor in analog technology. He also was, on occasions, an evangelist for analog technology. However, he found that National Semiconductor under Amelio had too few product offerings. Halla embarked on a diversification into personal computer and graphics business. He advocated PC-on-a-chip (aka system-on-a-chip) as a business direction for National Semiconductor. During his tenure at LSI, LSI had successfully applied similar concepts. However, LSI had steered clear of getting involved with PC technologies that would make it a competitor with Intel. Halla held the vision that information appliances (IAs) would succeed the personal computer as a trend. He predicted that IAs would overtake sales of PCs by the year 2000. To achieve the goal, National Semiconductor started acquiring companies that would provide the needed technological complements. Among the acquisitions were Cirrus Logic Inc's PicoPower business, for its specialised expertise in small form factor devices; Mediamatics Inc, which makes multimedia connectivity products; Future Integrated Systems Inc, a PC graphics company; Gulbransen Inc, a digital audio technology maker; ComCore Semiconductor Inc, a maker of digital signal processing for LANs; Cyrix, the maker of Intel x86 clones.

Sources: en.wikipedia.org

Supporting material

==== Insertion ==== The skin is sterilized and needles are inserted, frequently with a plastic guide tube. Needles may be manipulated in various ways, including spinning, flicking, or moving up and down relative to the skin. Since most pain is felt in the superficial layers of the skin, a quick insertion of the needle is recommended. Often the needles are stimulated by hand in order to cause a dull, localized, aching sensation that is called de qi, as well as "needle grasp," a tugging feeling felt by the acupuncturist and generated by a mechanical interaction between the needle and skin. Acupuncture can be painful. The acupuncturist's skill level may influence the painfulness of the needle insertion; a sufficiently skilled practitioner may be able to insert the needles without causing any pain.

== See also == Trade Incense trade route, a large network around the Mediterranean and beyond Land of Frankincense (Frankincense Trail), site in Oman Nabataeans, a trader tribe Literature Desi Sangye Gyatso, author of a Tibetan herbal Historia Plantarum (Theophrastus book) Similar plants and products Agarwood Benzoin (resin) Copal Elemi, resin or tree Myrrh, resin Palo santo (Bursera graveolens), tree Pistacia lentiscus (mastic tree), and Mastic (plant resin)

== Structure == The human form of IAPP has the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, with a disulfide bridge between cysteine residues 2 and 7. Both the amidated C-terminus and the disulfide bridge are necessary for the full biological activity of amylin. IAPP is capable of forming amyloid fibrils in vitro. Within the fibrillization reaction, the early prefibrillar structures are extremely toxic to beta-cell and insuloma cell cultures. Later amyloid fiber structures also seem to have some cytotoxic effect on cell cultures. Studies have shown that fibrils are the end product and not necessarily the most toxic form of amyloid proteins/peptides in general. A non-fibril forming peptide (1–19 residues of human amylin) is toxic like the full-length peptide but the respective segment of rat amylin is not. It was also demonstrated by solid-state NMR spectroscopy that the fragment 20-29 of the human-amylin fragments membranes. Rats and mice have six substitutions (three of which are proline substitutions at positions 25, 28 and 29) that are believed to prevent the formation of amyloid fibrils, although not completely as seen by its propensity to form amyloid fibrils in vitro. Rat IAPP is nontoxic to beta-cells when overexpressed in transgenic rodents.

Exactly how LSD produces its effects is unknown, but it is thought that it may work in part by increasing glutamate release in the cerebral cortex and therefore excitation in this area, specifically in layer V. LSD, like many other drugs of recreational use, has been shown to activate DARPP-32-related pathways. The drug enhances dopamine D2 receptor protomer recognition and signaling of D2–5-HT2A heteromeric receptor complexes, which may contribute to its psychotropic effects. LSD has been shown to have low affinity for histamine H1 receptors, displaying antihistamine effects, although the significance of this at doses used in humans is unknown. David E. Nichols has suggested that there may be a pharmacological basis for some bad trips with LSD, with this thought to be related to LSD's metabolite 13-hydroxy-LSD, a highly potent dopamine D4 receptor agonist. LSD is a biased agonist that induces a conformation in serotonin 5-HT2 receptors that preferentially recruits β-arrestin over activating G proteins. It also has an exceptionally long residence time when bound to serotonin receptors lasting hours, consistent with the long-lasting effects of LSD despite its relatively rapid clearance. In rodents, LSD levels are undetectable by 8 hours post-dosing, yet LSD continues to produce partial interoceptive effects (54% responding) at this time point.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Where was Selank developed?

It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.

Is Selank found in nature?

No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.

How is purity determined?

Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.

Network